Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (Ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of Copd in More Than 20 Years
配合物合作伙伴維羅納製藥發佈Ohtuvayre™(Ensifentrine)獲FDA批准,這是20多年來的第一種吸入式新型COPD維持治療機制。
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (Ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of Copd in More Than 20 Years
配合物合作伙伴維羅納製藥發佈Ohtuvayre™(Ensifentrine)獲FDA批准,這是20多年來的第一種吸入式新型COPD維持治療機制。
譯文內容由第三人軟體翻譯。